insitro's Daphne Koller on Why 90% of Drugs Fail & AI's Limits
ziv_ravid · x · 2026-08-05
In a recent interview, Daphne Koller (founder of Coursera and insitro) discussed the intersection of AI and drug discovery.
- The Bottleneck: 90% of drugs currently fail in clinical trials.
- AI's Limits: Pointing out that cells don't grow faster just by pointing more GPUs at them, she noted that most of biology remains out-of-distribution (OOD).
- Future Outlook: The conversation also touched on the Bitter Lesson in biology, the potential for agents in wet labs, and what it will take to build true foundation models for biology.
Related event: insitro CEO Daphne Koller: AI Drug Discovery Has No Magic Wand Yet(7 posts)→
More from Research
- Reverse-Engineering NVIDIA Blackwell Tensor Cores for Bit-for-Bit Software Simulation — ycombinator · 2026-08-05
- Analyzing the Four Core Paradigms of Modern In-Context TTS — rdesh26 · 2026-08-05
- Graph Analytics Benchmark Graph500 Selected for SPEC CPU 2026 Suite — Prof_DavidBader · 2026-08-05
- NeurIPS 2026 Competition: Predicting Fusion Plasma Equilibrium with ML — wattmaller1 · 2026-08-05
- Researcher Calls for a Refutations & Critiques Track at NeurIPS — RylanSchaeffer · 2026-08-05
- MuScriptor: Open-Weight Multi-Instrument Music Transcription Model Released — drscotthawley · 2026-08-05